What changed
$SNY — BUY 📊 | 6 MONTHS THESIS
🎯 latest | Rev $3.1B | EPS $1.10 vs $1.03 🟢
💡 Consensus models imply flat to low single-digit EPS growth due to patent cliff fears, but we see mid-single-digit growth from Dupixent's durable momentum, new launches (e.g., ALTUVIIIO), and cost discipline, driving 2025 EPS above $4.40 vs. implied ~$4.12, with a re-rating from 9.6x to 11x+.
📉 Reward/risk: 2.25:1
🏢 Business Quality: 7/10
📊 Valuation: cheap — TTM P/E 9.6x on annualized current EPS vs. large-cap pharma peer average ~13x and 5-year historical range 10-14x; additionally, FCF yield is...
🔮 Catalyst: Q2 2025 earnings release and potential positive Phase 3 data for Dupixent in COPD (BOREAS follow-up)
💰 Entry: $42.38, stop $39, target $50
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/SNY0620